Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Effect of Empagliflozin on Urinary Adenosine and Osteocyte Markers in CKD
NCT04961931Phase 4Unknown
- Sponsor
- Medical University of Lodz
- Start
- Jan 2019
- Primary completion
- Aug 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of empagliflozin in chronic kidney disease (CKD) and diabetic nephropathy (DN) (3 arms), sponsored by Medical University of Lodz. Primary endpoints: Albuminuria at 7 days, Serum Calcium Concentration at 7 days and 9 more. Status: unknown.
02
Drugs
empagliflozin
03
Conditions
chronic kidney disease (CKD)diabetic nephropathy (DN)
Beyond the preview
Go deeper on NCT04961931.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04961931.